Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

PHASE3RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

June 24, 2026

Study Completion Date

June 30, 2026

Conditions
Familial Adenomatous Polyposis
Interventions
DRUG

celecoxib monotherapy

Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.

DRUG

celecoxib and metformin combination

Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.

Trial Locations (1)

120-752

RECRUITING

Department of Internal Medicine, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER